WO2026067838A1: Define the Recognition Core
This application describes polypeptide compounds directed at IL-23R. For a design team, the useful first pass is to map its generic formula against concrete examples: residue identity, stereochemistry, cyclization site, ring size, exocyclic tail and any substituents. The generic formula shows a permitted design space; it is not a single experimentally characterized molecule.
In an internal design exercise, the application can motivate a target-interface assessment: which residues may maintain receptor engagement, where cyclic constraint might orient the pharmacophore, and which positions may tolerate substitution. These are hypotheses for separate structural and experimental work. A virtual pose cannot prove the binding mode, and receptor affinity does not by itself establish pathway inhibition, selectivity or oral exposure.
Read the compound examples and assay conditions alongside the claims. The comparison is most informative when the same test system, concentration range and definition of activity are used. When a numerical result is missing or only a broad category is reported, it should remain an uncertainty in any cross-patent ranking.